– USA, MA – Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced the appointment of Dr. Denis Patrick (Ph.D.), to its Board of Directors.
“Denis’ experience at multiple major biopharmaceutical companies and his knowledge of oncologic drug discovery will contribute greatly to Palleon’s mission to develop better therapies for patients. We are thrilled to welcome him to our Board and look forward to collaborating with him as we continue to move forward with the company’s drug discovery and development initiatives into 2022 and beyond. Denis will replace Dr. Nikola Trbovic, whom we would like to thank for his many contributions to Palleon during 2021,” said CEO, Dr. Jim Broderick.
About Dr. Denis Patrick
Dr. Patrick is VP and Head of Partnering Innovation at Pfizer and a Managing Partner at Pfizer Ventures, the venture capital arm of Pfizer Inc.
Currently, Dr. Patrick serves as a Board member of FoRx Therapeutics, Metabomed, Mission Therapeutics, and EvolveImmune Therapeutics. Before joining Pfizer Ventures, Dr. Patrick served as Head of Oncology Licensing for Worldwide R&D at Pfizer, where he executed the acquisitions of Medivation and BIND Therapeutics and secured research licenses with eight biopharmaceutical companies.
Before his work at Pfizer, Dr. Patrick served as Director of Oncology Scientific Licensing and Business Development at GlaxoSmithKline, where he was responsible for evaluating clinical and pre-clinical oncologic drugs for potential in-licensing. He began his career as a research scientist at Merck in the drug discovery sector for cancer. Dr. Patrick earned his Ph.D. in biochemistry from the University of Pennsylvania.
“Palleon is charting new possibilities in immuno-oncology thanks to their scientific leadership in the field of glycobiology, and it’s an exciting time to join those efforts. As a member of the Board, I look forward to collaborating with this exceptional team to improve and extend the lives of patients suffering from serious diseases,” said Dr. Patrick.
About Palleon Pharmaceuticals
Palleon Pharmaceuticals is the leading biotechnology company developing drugs that harness glyco-immunology to treat cancer and inflammatory diseases. The company’s proprietary platforms overcome scientific hurdles that limited progress in the glycobiology field to create novel therapeutics for devastating diseases characterized by immune system dysfunction. Palleon’s lead program in oncology, E-602, is an enzymatic degrader of immunosuppressive sialoglycans on tumors and immune cells which is expected to enter clinical testing in refractory cancer patients in early 2022.
For more information: htps://palleonpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.